British Journal of Cancer

Fig. 1: Patient survivals of Arm A versus Arm B. | British Journal of Cancer

Fig. 1: Patient survivals of Arm A versus Arm B.

From: Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial

Fig. 1: Patient survivals of Arm A versus Arm B.

Search

Advanced search

Quick links